Literature DB >> 21653835

Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.

Jantine E Bakema1, Sonja H Ganzevles, Donna M Fluitsma, Marco W Schilham, Robert H J Beelen, Thomas Valerius, Stefan Lohse, Martin J Glennie, Jan Paul Medema, Marjolein van Egmond.   

Abstract

Neutrophils are the most abundant circulating FcR-expressing WBCs with potent cytotoxic ability. Currently, they are recognized as promising effector cells for Ab-mediated immunotherapy of cancer, because their capacity to kill tumor cells is greatly enhanced by tumor Ag-specific mAbs. The FcαRI represents the most potent FcR on neutrophils for induction of Ab-mediated tumor cell killing. However, the mechanisms of cell death that are induced are poorly understood. Because these mechanisms can be used for modulation of anticancer treatment, we investigated the tumor cell death induced by neutrophil-mediated Ab-dependent killing via FcαRI. Human mammary carcinoma cells were efficiently killed when incubated with human neutrophils and tumor-specific FcαRI bispecific or IgA Abs. Interestingly, we observed characteristics of autophagy such as autophagic structures by electron microscopy and LC3B(+) autophagosomes in different human epithelial carcinoma cells, which resulted in tumor cell death. To a lesser extent, necrotic features, such as cellular membrane breakdown and spillage of intracellular content, were found. By contrast, apoptotic features including fragmented nuclei, Annexin V-positivity, and presence of cleaved caspase-3 were not observed. These findings indicate that neutrophils mainly facilitate autophagy to induce tumor cell death rather than the more commonly recognized apoptotic cell death mechanisms induced by NK cells or cytotoxic T cells. This knowledge not only reveals the type of tumor cell death induced in neutrophil-mediated, Ab-dependent cellular cytotoxicity, but importantly opens up additional perspectives for modulation of anticancer therapy in, for example, apoptosis-resistant tumor cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21653835     DOI: 10.4049/jimmunol.1002581

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Immunoglobulin A: A next generation of therapeutic antibodies?

Authors:  Jantine E Bakema; Marjolein van Egmond
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

2.  IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.

Authors:  Eric D Frontera; Rafa M Khansa; Dana L Schalk; Lauren E Leakan; Tracey J Guerin-Edbauer; Manohar Ratnam; David H Gorski; Cecilia L Speyer
Journal:  Breast Cancer Res Treat       Date:  2018-08-28       Impact factor: 4.872

3.  Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.

Authors:  Niels Heemskerk; Mandy Gruijs; A Robin Temming; Marieke H Heineke; Dennis Y Gout; Tessa Hellingman; Cornelis W Tuk; Paula J Winter; Suzanne Lissenberg-Thunnissen; Arthur Eh Bentlage; Marco de Donatis; Marijn Bögels; Thies Rösner; Thomas Valerius; Jantine E Bakema; Gestur Vidarsson; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

Review 4.  Protumor and antitumor functions of neutrophil granulocytes.

Authors:  Sven Brandau; Claudia A Dumitru; Stephan Lang
Journal:  Semin Immunopathol       Date:  2012-09-25       Impact factor: 9.623

5.  iPLA2 Activation Mediates Granular Exocytosis and Corrects Microbicidal Defects in ROS-Deficient and CGD Human Neutrophils.

Authors:  Issam Harfi; Stéphanie D'Hondt; Eric Sariban
Journal:  J Clin Immunol       Date:  2019-06-01       Impact factor: 8.317

Review 6.  Autophagy in immunity: implications in etiology of autoimmune/autoinflammatory diseases.

Authors:  Xu-Jie Zhou; Hong Zhang
Journal:  Autophagy       Date:  2012-08-14       Impact factor: 16.016

Review 7.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

Review 8.  Nanotechnology for protein delivery: Overview and perspectives.

Authors:  Mikyung Yu; Jun Wu; Jinjun Shi; Omid C Farokhzad
Journal:  J Control Release       Date:  2015-10-13       Impact factor: 9.776

9.  Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8.

Authors:  Xiaocong Yu; Mark Duval; Christopher Lewis; Melissa A Gawron; Rijian Wang; Marshall R Posner; Lisa A Cavacini
Journal:  J Immunol       Date:  2012-11-26       Impact factor: 5.422

10.  Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI.

Authors:  Fabian Bohländer; Dennis Riehl; Sabrina Weißmüller; Marcus Gutscher; Jörg Schüttrumpf; Stefanie Faust
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.